Fintel reports that on January 5, 2025, BNP PARIBAS EXANE upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Neutral ...

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $83.34, denoting a -1.99% change from the preceding trading day.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock ...

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at Sanford C. Bernstein from an “underperform” rating to a “market perform” rating in a research note issued on ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

The millennial-focused digital health company Hims & Hers (HIMS) has donated $1 million to President-elect Donald Trump’s ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...

Investors in Novo-Nordisk AS (Symbol: NVO) saw new options begin trading today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVO ...

The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity. NVO is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of A and VGM Score ...